Financials in USD. Standardized financial statements.
A compact view of how Organon & Co. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B | $6.53B | $7.78B | $9.78B | $10.50B |
| Revenue Growth? | -2.9% | +2.2% | +1.4% | -2.1% | -3.5% | -16.0% | -20.5% | -6.9% | 0.0% |
| Cost of Revenue? | $2.85B | $2.69B | $2.52B | $2.29B | $2.38B | $2.12B | $2.27B | $4.69B | $4.59B |
| Gross Profit? | $3.36B | $3.71B | $3.75B | $3.88B | $3.92B | $4.41B | $5.50B | $5.08B | $5.91B |
| Gross Margin? | +54.1% | +58.0% | +59.8% | +62.8% | +62.2% | +67.6% | +70.8% | +52.0% | +56.3% |
| Operating Expenses? | $2.09B | $2.23B | $2.42B | $2.17B | $2.01B | $1.57B | $1.66B | $2.38B | $2.64B |
| Operating Income? | $1.28B | $1.49B | $1.33B | $1.71B | $1.92B | $2.85B | $3.85B | $2.71B | $3.27B |
| EBITDA? | $1.28B | $1.60B | $1.44B | $1.76B | $1.98B | $2.99B | $3.92B | $4.38B | $5.08B |
| Income Before Tax | $425.00M | $807.00M | $673.00M | $1.12B | $1.53B | $2.75B | $3.70B | $2.73B | $3.10B |
| Income Tax Expense | $238.00M | -$57.00M | -$350.00M | $205.00M | $178.00M | $496.00M | $390.00M | $576.00M | $1.30B |
| Net Income? | $187.00M | $864.00M | $1.02B | $917.00M | $1.35B | $2.16B | $3.22B | $2.15B | $1.80B |
| EPS? | $0.72 | $3.36 | $4.01 | $3.61 | $5.33 | $8.52 | $12.71 | $8.51 | $7.11 |
| Diluted EPS? | $0.72 | $3.33 | $3.99 | $3.59 | $5.33 | $8.52 | $12.71 | $8.51 | $7.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality